CARB-X funds Polyphor to develop a new class of antibiotics to treat serious infections caused by Gram- negative ESKAPE superbugs

CARB-X, a Boston University global partnership, is awarding Polyphor (SIX: POLN) of Allschwil, Switzerland, up to $2.6 million in non-dilutive funding with the possibility of $3.0 million more if certain project milestones are met, to develop a novel antibiotic with a novel mode of action to treat serious infections caused by Gram-negative ESKAPE pathogens.

Article: CARB-X

Smart Innovations  

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed